Updated Aug 10 at 7:01pm ET.
Follow Revolution Medicines to never miss an important update.
Wolfe Research raised its price target for the stock from $165 to $220. This is a large increase of about 33 percent, reflecting higher confidence in the company's path forward.
The move comes as the company transitions from a research-focused firm into one preparing to sell its first drugs. Analysts are increasingly factoring in the potential for these therapies to become the new standard of care for difficult-to-treat tumors like pancreatic cancer.
Source: Wolfe Research
Revolution Medicines is teaming up with BeOne Medicines to study how their respective cancer drugs work when used together. This type of clinical collaboration is common in oncology, as combining different treatments can often hit tumors more effectively than a single drug alone.
Beyond the research, the deal includes a plan for BeOne to handle the commercial launch of Revolution's therapies in China. This is a smart way for a younger company to reach a massive international market without the high cost and risk of building its own sales team and navigating local regulations from scratch.
Source: Business Wire
Oppenheimer raised its price target for the stock from $195 to $230 while keeping its buy rating. This adjustment reflects growing confidence in the company's lead drug candidate, daraxonrasib, as it moves closer to potential regulatory approval.
While the company is still spending heavily on research and losing money, analysts are increasingly focused on the multibillion-dollar potential of its cancer platform. This target increase suggests that the recent progress in clinical trials is outweighing the risks of the company's current lack of revenue.
Source: Oppenheimer
The company reported a loss of $3.06 per share for the quarter, which was more than the $2.04 loss analysts had expected. As a late-stage biotech firm, it still generates no revenue and is spending heavily on the expensive final stages of testing its drug candidates.
The focus for long-term owners is on the timeline for daraxonrasib, its lead drug for pancreatic cancer. Management expects to finish enrolling patients in its main Phase 3 trial this year, which keeps it on track to share final results in 2026. It is also starting new trials for lung cancer and earlier stages of pancreatic cancer. While the losses are high, the company is using its cash to move several high-potential treatments toward the finish line at once.
Source: 8-K filing
The FDA accepted the company's New Drug Application for daraxonrasib, a major milestone that moves the treatment one step closer to the market. This application specifically targets patients with pancreatic cancer that has spread and has already been treated with other therapies.
This is a critical step in the company's transition from a research firm to a commercial business. If approved, daraxonrasib would be the first product the company can actually sell. Pancreatic cancer is notoriously difficult to treat, and an approval here would validate the company's entire approach to targeting cancer proteins.
Source: GlobeNewsWire
Analysts have been aggressively raising their price targets following the company's recent earnings report and new partnership announcement. Nearly all 23 analysts rate the stock a buy, though the average target of $204 is slightly below today's price.
The company has missed analyst estimates for eight straight quarters. This is common for a firm at this stage, as the high costs of running global clinical trials are difficult to predict.
| Expectation | |
|---|---|
| EPS | $-2.31 |
| Revenue | $8M |
Business Wire · Press release · Aug 10
Seeking Alpha · Opinion · Aug 7
Seeking Alpha · Opinion · Aug 5
GlobeNewsWire · Press release · Aug 5
GlobeNewsWire · Press release · Jul 29
Follow Revolution Medicines to get the latest and most important updates.
Follow RVMD